TY - JOUR
T1 - Circulating concentrations of insulin resistance-associated hepatokines, selenoprotein P and leukocyte cell-derived chemotaxin 2, during an oral glucose tolerance test in humans
AU - Mohri, Kensuke
AU - Misu, Hirofumi
AU - Takayama, Hiroaki
AU - Ishii, Kiyo aki
AU - Kikuchi, Akihiro
AU - Lan, Fei
AU - Enyama, Yasufumi
AU - Takeshita, Yumie
AU - Saito, Yoshiro
AU - Kaneko, Shuichi
AU - Takamura, Toshinari
N1 - Funding Information:
Acknowledgments We thank for Mutsumi Tanaka (Al-fresa Pharma Corporation) for technical assistance of SeP measurement. This work was supported by JSPS KAKENHI Grants 16K09740 (H.M.).
Publisher Copyright:
© 2019 The Pharmaceutical Society of Japan.
PY - 2019
Y1 - 2019
N2 - A hepatokine is a collective term for liver-derived secretory factors whose previously-unrecognized functions have been recently elucidated. We have rediscovered selenoprotein P (SeP) and leukocyte cell-derived chemotaxin 2 (LECT2) as hepatokines that are involved in the development of insulin resistance and hyperglycemia. The aim of this study was to determine whether and, if so, how oral glucose loading alters the two hepatokines in humans. We measured concentrations of serum SeP and plasma LECT2 during 75g oral glucose tolerance test (OGTT) (n=20) in people with various degrees of glucose tolerance. In OGTT, concentrations of both serum SeP and plasma LECT2 decreased at 120min compared with the baseline values, irrespective of the severity of glucose intolerance. Decrement of serum SeP during OGTT showed no correlations to the clinical parameters associated with insulin resistance or insulin secretion. In multiple stepwise regression analyses, plasma cortisol was selected as the variable to explain the changes in plasma concentrations of LECT2. The current data reveal the acute inhibitory actions of oral intake of glucose on circulating SeP and LECT2 in humans, irrespective of the severity of glucose intolerance. This study suggests that circulating SeP is regulated by the unknown clinical factors other than insulin and glucose during OGTT.
AB - A hepatokine is a collective term for liver-derived secretory factors whose previously-unrecognized functions have been recently elucidated. We have rediscovered selenoprotein P (SeP) and leukocyte cell-derived chemotaxin 2 (LECT2) as hepatokines that are involved in the development of insulin resistance and hyperglycemia. The aim of this study was to determine whether and, if so, how oral glucose loading alters the two hepatokines in humans. We measured concentrations of serum SeP and plasma LECT2 during 75g oral glucose tolerance test (OGTT) (n=20) in people with various degrees of glucose tolerance. In OGTT, concentrations of both serum SeP and plasma LECT2 decreased at 120min compared with the baseline values, irrespective of the severity of glucose intolerance. Decrement of serum SeP during OGTT showed no correlations to the clinical parameters associated with insulin resistance or insulin secretion. In multiple stepwise regression analyses, plasma cortisol was selected as the variable to explain the changes in plasma concentrations of LECT2. The current data reveal the acute inhibitory actions of oral intake of glucose on circulating SeP and LECT2 in humans, irrespective of the severity of glucose intolerance. This study suggests that circulating SeP is regulated by the unknown clinical factors other than insulin and glucose during OGTT.
KW - Hepatokine
KW - Leukocyte cell-derived chemotaxin 2
KW - Oral glucose tolerance test
KW - Selenoprotein P
UR - http://www.scopus.com/inward/record.url?scp=85062391818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062391818&partnerID=8YFLogxK
U2 - 10.1248/bpb.b18-00549
DO - 10.1248/bpb.b18-00549
M3 - Article
C2 - 30606895
AN - SCOPUS:85062391818
SN - 0918-6158
VL - 42
SP - 373
EP - 378
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 3
ER -